AQR Capital Management
KYMR icon

AQR Capital Management’s Kymera Therapeutics KYMR Stock Holding History

AQR Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
9,541
-6,410
-40% -$551K ﹤0.01% 2957
2026
Q1 		$1.33M Buy
15,951
+6,612
+71% +$524K ﹤0.01% 2621
2025
Q4 		$727K Buy
9,339
+719
+8% +$48.6K ﹤0.01% 2720
2025
Q3 		$488K Buy
8,620
+537
+7% +$24.2K ﹤0.01% 2825
2025
Q2 		$353K Buy
+8,083
New +$278K ﹤0.01% 2780
2025
Q1 		– Sell
-6,576
Closed -$265K – 3173
2024
Q4 		$265K Sell
6,576
-5,684
-46% -$257K ﹤0.01% 2558
2024
Q3 		$580K Buy
+12,260
New +$541K ﹤0.01% 2101

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

AQR Capital Management's KYMR Position: Q2 2026 in Review

AQR Capital Management reduced its Kymera Therapeutics (KYMR) stake by 40% in Q2 2026, selling an estimated $551K and leaving 9,541 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2957.

AQR Capital Management first reported a position in KYMR in Q3 2024 and has held it in 7 quarters since. The position peaked at $1.33M in Q1 2026. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • AQR Capital Management held 9,541 shares of Kymera Therapeutics worth $1.09M as of Q2 2026.
  • AQR Capital Management sold 6,410 Kymera Therapeutics shares in Q2 2026, an estimated $551K.
  • Kymera Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #2957 holding.
  • AQR Capital Management first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • AQR Capital Management's Kymera Therapeutics position peaked at $1.33M in Q1 2026.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.